drugset / Trial / NCT05194163
MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease
Phase 2
Unknown
24 enrolled
Neurokine Therapeutics
Columbia University · collabNational Institute on Aging (NIA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a phase 2a randomized double-blind, placebo-controlled, study, in mild-to-moderate Alzheimer's disease, of the oral investigational drug MW150, a p38alphaMAPK kinase inhibitor. The primary goals of this study are to investigate the safety and tolerability, and drug movements in the body. The secondary goals of the study are to investigate the effects of the drug on cognitive performance, activities of daily living, and behavior, and the biological effects of the drug on blood biomarkers.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2024-08-31
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MW150 | Small molecule | 10 mg | Oral |